Literature DB >> 25779752

Cardiovascular pathobiology of inflammasomes: inflammatory machinery and beyond.

Pin-Lan Li1.   

Abstract

SIGNIFICANCE: In response to infection or cellular stress, inflammasomes are assembled and activated to mediate host defense and to initiate or promote the development of different diseases, in particular, autoinflammatory diseases and chronic degenerative diseases. Understanding of inflammasomes and related physiological and pathological relevance to the cardiovascular system will open a new chapter on the pathogenesis of inflammation and related diseases and will help develop novel therapeutic strategies for prevention or treatment of cardiovascular diseases. RECENT ADVANCES: The inflammasome, in particular the nucleotide oligomerization domain-like receptor containing pyrin domain 3 (NLRP3) inflammasome, has been recently recognized as a fundamental mechanism to mediate or promote the pathogenesis of degenerative diseases. Some important mechanisms responsible for NLRP3 inflammasome activation have been proposed and many molecular targets associated with this inflammasome activation are shown to be the possible candidates of therapeutic targets for treatment of cardiovascular diseases. CRITICAL ISSUES: The concepts that NLRP3 inflammasome activation occurs just in immune cells or phagocytes and that its role is only for the inflammatory progression of cardiovascular diseases are oversimplified. A large body of other cell types are capable of NLRP3 inflammasome activation, and many uncanonical effects of this inflammasome may also be implicated in the development of cardiovascular diseases, which are discussed in a great detail by this Forum. FUTURE DIRECTIONS: More mechanistic and translational studies will rapidly widen the horizon of knowledge on NLRP3 inflammasome activation and regulation, which may help develop novel effective therapeutic strategies to target this inflammasome for treatment or prevention of cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25779752      PMCID: PMC4403011          DOI: 10.1089/ars.2015.6319

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  9 in total

1.  GSK's darapladib failures dim hopes for anti-inflammatory heart drugs.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2014-07       Impact factor: 84.694

Review 2.  Redox regulation of NLRP3 inflammasomes: ROS as trigger or effector?

Authors:  Justine M Abais; Min Xia; Yang Zhang; Krishna M Boini; Pin-Lan Li
Journal:  Antioxid Redox Signal       Date:  2015-01-19       Impact factor: 8.401

Review 3.  The inflammasome in myocardial injury and cardiac remodeling.

Authors:  Stefano Toldo; Eleonora Mezzaroma; Adolfo Gabriele Mauro; Fadi Salloum; Benjamin Wallace Van Tassell; Antonio Abbate
Journal:  Antioxid Redox Signal       Date:  2014-12-11       Impact factor: 8.401

Review 4.  Role of inflammasome activation in the pathophysiology of vascular diseases of the neurovascular unit.

Authors:  Islam N Mohamed; Tauheed Ishrat; Susan C Fagan; Azza B El-Remessy
Journal:  Antioxid Redox Signal       Date:  2014-11-11       Impact factor: 8.401

Review 5.  Hierarchical regulation of wound healing by NOD-like receptors in cardiovascular disease.

Authors:  Nathan A Bracey; Henry J Duff; Daniel A Muruve
Journal:  Antioxid Redox Signal       Date:  2014-11-10       Impact factor: 8.401

Review 6.  Implication of pattern-recognition receptors in cardiovascular diseases.

Authors:  Xiaojie Wang; Fan Yi
Journal:  Antioxid Redox Signal       Date:  2015-01-14       Impact factor: 8.401

7.  Coronary endothelial dysfunction induced by nucleotide oligomerization domain-like receptor protein with pyrin domain containing 3 inflammasome activation during hypercholesterolemia: beyond inflammation.

Authors:  Yang Zhang; Xiang Li; Ashley L Pitzer; Yang Chen; Lei Wang; Pin-Lan Li
Journal:  Antioxid Redox Signal       Date:  2015-03-31       Impact factor: 8.401

Review 8.  Molecular activation of the NLRP3 Inflammasome in fibrosis: common threads linking divergent fibrogenic diseases.

Authors:  Carol M Artlett; James D Thacker
Journal:  Antioxid Redox Signal       Date:  2014-12-09       Impact factor: 8.401

9.  Pseudomonas aeruginosa pyocyanin induces neutrophil death via mitochondrial reactive oxygen species and mitochondrial acid sphingomyelinase.

Authors:  Antonella Managò; Katrin Anne Becker; Alexander Carpinteiro; Barbara Wilker; Matthias Soddemann; Aaron P Seitz; Michael J Edwards; Heike Grassmé; Ildiko Szabò; Erich Gulbins
Journal:  Antioxid Redox Signal       Date:  2015-03-18       Impact factor: 8.401

  9 in total
  10 in total

1.  NLRP3 inflammasome as a novel target for docosahexaenoic acid metabolites to abrogate glomerular injury.

Authors:  Guangbi Li; Zhida Chen; Owais M Bhat; Qinghua Zhang; Justine M Abais-Battad; Sabena M Conley; Joseph K Ritter; Pin-Lan Li
Journal:  J Lipid Res       Date:  2017-04-12       Impact factor: 5.922

2.  NLRP3 inflammasome: common nexus between depression and cardiovascular diseases.

Authors:  Elísabet Alcocer-Gómez; Mario D Cordero
Journal:  Nat Rev Cardiol       Date:  2017-01-05       Impact factor: 32.419

Review 3.  Inflammasome Activation in Chronic Glomerular Diseases.

Authors:  Sabena M Conley; Justine M Abais; Krishna M Boini; Pin-Lan Li
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

Review 4.  Emerging Roles of Inflammasomes in Cardiovascular Diseases.

Authors:  Yingnan Liao; Kui Liu; Liyuan Zhu
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

Review 5.  Regulatory Mechanisms of the NLRP3 Inflammasome, a Novel Immune-Inflammatory Marker in Cardiovascular Diseases.

Authors:  Na An; Yonghong Gao; Zeyu Si; Hanlai Zhang; Liqin Wang; Chao Tian; Mengchen Yuan; Xinyu Yang; Xinye Li; Hongcai Shang; Xingjiang Xiong; Yanwei Xing
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561

6.  ELABELA attenuates deoxycorticosterone acetate/salt-induced hypertension and renal injury by inhibition of NADPH oxidase/ROS/NLRP3 inflammasome pathway.

Authors:  Zhida Chen; Chunying Wu; Yuting Liu; Haonan Li; Yeyan Zhu; Cailing Huang; Huangbo Lin; Qiao Qiao; Mengming Huang; Qing Zhu; Lei Wang
Journal:  Cell Death Dis       Date:  2020-08-22       Impact factor: 8.469

7.  Ulinastatin protects against sepsis‑induced myocardial injury by inhibiting NLRP3 inflammasome activation.

Authors:  Juanjuan Qiu; Xiaoguang Xiao; Xue Gao; Yongli Zhang
Journal:  Mol Med Rep       Date:  2021-08-20       Impact factor: 2.952

Review 8.  Mitochondrial Arrest on the Microtubule Highway-A Feature of Heart Failure and Diabetic Cardiomyopathy?

Authors:  Sarah Kassab; Zainab Albalawi; Hussam Daghistani; Ashraf Kitmitto
Journal:  Front Cardiovasc Med       Date:  2021-07-02

9.  NLRP3 Inflammasome Formation and Activation in Nonalcoholic Steatohepatitis: Therapeutic Target for Antimetabolic Syndrome Remedy FTZ.

Authors:  Yu Chen; Xingxiang He; Xinxu Yuan; Jinni Hong; Owais Bhat; Guangbi Li; Pin-Lan Li; Jiao Guo
Journal:  Oxid Med Cell Longev       Date:  2018-07-22       Impact factor: 6.543

10.  Cardiometabolic Effects of Irisin in Patients with End-Stage Renal Disease on Regular Hemo- or Peritoneal Dialysis.

Authors:  Botond Csiky; Balázs Sági; Vanessza Emmert; István Wittmann; Endre Sulyok
Journal:  Blood Purif       Date:  2021-08-02       Impact factor: 3.348

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.